loading page

An anti-bacterial monoclonal antibody that targets pathogenic bacteria expressing the type 3 secretion system for therapeutic and diagnostic applications
  • +5
  • Yaron Hillman,
  • Jenia Gechtler,
  • Dan Lustiger,
  • Dan Even,
  • Dor Braverman,
  • Yael Dror,
  • Neta Sal-Man,
  • Yariv Wine
Yaron Hillman
Tel Aviv University
Author Profile
Jenia Gechtler
Ben-Gurion University of the Negev Faculty of Health Sciences
Author Profile
Dan Lustiger
Tel Aviv University
Author Profile
Dan Even
Tel Aviv University
Author Profile
Dor Braverman
Ben-Gurion University of the Negev Faculty of Health Sciences
Author Profile
Yael Dror
Tel Aviv University
Author Profile
Neta Sal-Man
Ben-Gurion University of the Negev Faculty of Health Sciences
Author Profile
Yariv Wine
Tel Aviv University
Author Profile

Abstract

It is predicted that failure to address the antibiotic-resistance crisis will result in an annual death rate of 10 million people by the year 2050. To grapple with the challenges of the impending crisis, there is an urgent need for novel anti-bacterial agents and rapid diagnostic tools. Here, we developed a novel monoclonal antibody – known as mAb-EspB-B7 – that targets EspB, a component within the bacterial type 3 secretion system (T3SS), which is mainly expressed in Gram-negative pathogens and is essential for bacterial infectivity. We found that mAb-EspB-B7 has high affinity and specificity towards recombinant and native EspB proteins, is stable over a range of pH levels, temperatures and salt concentrations, and retains its functionality in human serum. We identified the epitope for mAb-EspB-B7 and validated it by competitive ELISA. Since this epitope is conserved across several T3SS-harboring pathogens, mAb-EspB-B7 holds great potential for development as an anti-bacterial agent or as the active component in precise and rapid diagnostic tools.